Provided are novel compounds that inhibit LRRK2 kinase activity, processes for their preparation, compositions containing them and their use in the treatment of or prevention of diseases associated with or characterized by LRRK2 kinase activity, for example Parkinson's disease, Alzheimer's disease and amyotrophic lateral sclerosis (ALS).
Sterically hindered (pyridyl)benzamidine palladium(II) complexes: Syntheses, structural studies, and applications as catalysts in the methoxycarbonylation of olefins
作者:Saphan O. Akiri、Stephen O. Ojwach
DOI:10.1002/aoc.6439
日期:2021.12
afford square planar compounds. Activation of the palladium(II) complexes with para-tolyl sulfonic acid (PTSA) afforded activecatalysts in the methoxycarbonylation of a number of alkene. The resultant catalytic activities were controlled by the both the complex structure and alkene substrate. While aliphaticsubstrates favored the formation of linear esters (>70%), styrene substrate resulted in the formation
The analysis of the volatiles released by the novel bacterial isolate ChitinophagaFx7914 revealed the presence of ca. 200 compounds including different methylesters. These esters comprise monomethyl- and dimethyl-branched, saturated, and unsaturated fatty acid methylesters that have not been described as bacterial volatiles before. More than 30 esters of medium C-chain length were identified, which
Methoxycarbonylation of olefins catalysed by homogeneous palladium(II) complexes of (phenoxy)imine ligands bearing alkoxy silane groups
作者:Saphan O. Akiri、Stephen O. Ojwach
DOI:10.1016/j.ica.2019.02.025
日期:2019.4
[Pd(L1)2] (1) and [Pd(L2)2] (2), treatments of HL1 and HL2 with [Pd(NCMe)2Cl2] gave the mono(chelated) complexes [Pd(HL1)2Cl2] (3) and [Pd(HL2)2Cl2] (4) respectively. Structural characterization of the compounds was achieved using NMR and FT-IR spectroscopies, mass spectrometry and micro-analyses. Complexes 1–4 gave active catalysts in the methoxycarbonylation of higher olefins producing linear esters as